Entry Detail



General Information

Database ID:exR0357753
RNA Name:hsa-miR-520a-3p
RNA Type:miRNA
Chromosome:chr19
Starnd:+
Coordinate:
Start Site(bp):53690933End Site(bp):53690954
External Links:hsa-miR-520a-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE98181
Description:Circulating miRNA profiles from serum of women at high-risk for breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:NA
Case Sample:Breast Cancer
Control Sample:Healthy
Number of Case:24
Number of Control:24
Number of Samples:48





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
SEMA3C
chr7
80742538
80922359
-
APP
chr21
25880550
26171128
-
IKZF4
chr12
56007659
56038435
+
MAGI3
chr1
113390515
113685923
+
HTD2
chr3
58306262
58318574
+
RPP14
chr3
58306247
58324695
+
CELF2
chr10
10798397
11336675
+
SLC7A2
chr8
17497088
17570573
+
SYAP1
chrX
16719612
16765340
+
FYCO1
chr3
45917899
45995824
-
PDRG1
chr20
31944337
31952046
-
OCRL
chrX
129539849
129592561
+
CLIP4
chr2
29097705
29189643
+
COL4A2
chr13
110305812
110513209
+
CDK6
chr7
92604921
92836594
-
PLAGL2
chr20
32192504
32207743
-
CLCN6
chr1
11806096
11848079
+
MNT
chr17
2384073
2401104
-
XRRA1
chr11
74807739
74949200
-
ZFAND4
chr10
45615500
45672780
-
CCDC93
chr2
117915478
118014133
-
UCHL1
chr4
41256413
41268455
+
MSL1
chr17
40121971
40136917
+
RACGAP1
chr12
49976923
50033136
-
KIAA1522
chr1
32741830
32774970
+
BTN3A1
chr6
26402237
26415208
+
MBP
chr18
76978827
77133683
-
RGMA
chr15
93035273
93089204
-
CUL1
chr7
148697914
148801110
+
TRIM37
chr17
58982638
59106921
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000943
chr19
47421744
47440665
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC125257.1
chr17
41848518
41851447
-
AL049840.4
chr14
103694516
103695050
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
FGD5-AS1
chr3
14920347
14948424
-
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE98181
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21572
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2546
Sample treatment protocol:Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes.
RNA Extract protocol:RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water.
RNA library preparation protocol:Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.



Reference

PMID:29348816
Title:Development of a predictive miRNA signature for breast cancer risk among high-risk women.
Author:Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME
Journal:Oncotarget. 2017 Nov 28;8(68):112170-112183.
Description:We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.